Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer

International Journal of Molecular Sciences

Volumn 16, Issue 2, 2015, Pages 2472-2496

  Ng, Jennifer Mun Kar ^a   Yu, Jun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Biomarkers; Colorectal cancer; CpG islands; Promoter methylation; Tumour suppressor gene

Indexed keywords

ALPHA4 INTEGRIN; APC PROTEIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR; GATA BINDING PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; MICROSATELLITE DNA; NERVE GROWTH FACTOR RECEPTOR; NEUROGENIN 1; NUCLEAR PROTEIN; OSTEOGENIN; PROTEIN P53; SECRETED FRIZZLED RELATED PROTEIN 2; SEPTIN; SEPTIN 9; TISSUE FACTOR PATHWAY INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR RUNX; UNCLASSIFIED DRUG; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ANGIOGENESIS; APOPTOSIS; BLOOD ANALYSIS; CANCER PROGNOSIS; CARCINOGENESIS; CELL ADHESION; CELL CYCLE REGULATION; CELL INVASION; COLORECTAL CANCER; CPG ISLAND METHYLATOR PHENOTYPE; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FECES ANALYSIS; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; PHENOTYPE; PROMOTER REGION; REGULATOR GENE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; VIRUS ONCOGENE; BLOOD; COLORECTAL TUMOR; CPG ISLAND; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MICRORNAS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84921874682     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16022472     Document Type: Review

References (149)

1. Ferlay, J.; Soerjomataram, I.; dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359-E386.
2. Ferlay, J.; Shin, H.-R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
3. Toiyama, Y.; Okugawa, Y.; Goel, A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem. Biophys. Res. Commun. 2014, 455, 43-57.
4. O’Shaughnessy, J.A.; Kelloff, G.J.; Gordon, G.B.; Dannenberg, A.J.; Hong, W.K.; Fabian, C.J.; Sigman, C.C.; Bertagnolli, M.M.; Stratton, S.P.; Lam, S, et al. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development recommendations of the American Association for Cancer Research Task Force on the treatment and prevention of intraepithelial neoplasia. Clin. Cancer Res. 2002, 8, 314-346.
5. Lao, V.V.; Grady, W.M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol.2011, 8, 686-700.
6. Fearon, E.R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. Mech. Dis. 2011, 6,479-507.
7. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
8. Schuebel, K.E.; Chen, W.; Cope, L.; Glöckner, S.C.; Suzuki, H.; Yi, J.-M.; Chan, T.A.; Neste, L.V.; Criekinge, W.V.; van den Bosch, S, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007, 3, e157.
9. Van Engeland, M.; Derks, S.; Smits, K.M.; Meijer, G.A.; Herman, J.G. Colorectal cancer epigenetics: Complex simplicity. J. Clin. Oncol. 2011, 29, 1382-1391.
10. Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis 2010, 31, 27-36.
11. Issa, J.-P. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 2004, 4, 988-993.
12. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16, 6-21.
13. Comb, M.; Goodman, H.M. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res. 1990, 18, 3975-3982.
14. Inamdar, N.M.; Ehrlich, K.C.; Ehrlich, M. CpG methylation inhibits binding of several sequence-specific DNA-binding proteins from pea, wheat, soybean and cauliflower. Plant Mol. Biol. 1991, 17, 111-123.
15. Campanero, M.R.; Armstrong, M.I.; Flemington, E.K. CpG methylation as a mechanism for the regulation of E2F activity. Proc. Natl. Acad. Sci. USA 2000, 97, 6481-6486.
16. Deng, G.; Chen, A.; Pong, E.; Kim, Y.S. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene 2001, 20, 7120-7127.
17. Bednarik, D.P.; Duckett, C.; Kim, S.U.; Perez, V.L.; Griffis, K.; Guenthner, P.C.; Folks, T.M. DNA CpG methylation inhibits binding of NF-κB proteins to the HIV-1 long terminal repeat cognate DNA motifs. New Biol. 1991, 3, 969-976.
18. Nan, X.; Ng, H.-H.; Johnson, C.A.; Laherty, C.D.; Turner, B.M.; Eisenman, R.N.; Bird, A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393, 386-389.
19. Baylin, S.; Bestor, T.H. Altered methylation patterns in cancer cell genomes: Cause or consequence? Cancer Cell 2002, 1, 299-305.
20. Suzuki, H.; Watkins, D.N.; Jair, K.-W.; Schuebel, K.E.; Markowitz, S.D.; Dong Chen, W.; Pretlow, T.P.; Yang, B.; Akiyama, Y.; van Engeland, M, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 2004, 36, 417-422.
21. Kit, A.H.; Nielsen, H.M.; Tost, J. DNA methylation based biomarkers: Practical considerations and applications. Biochimie 2012, 94, 2314-2337.
22. Costello, J.F.; Frühwald, M.C.; Smiraglia, D.J.; Rush, L.J.; Robertson, G.P.; Gao, X.; Wright, F.A.; Feramisco, J.D.; Peltomäki, P.; Lang, J.C, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 2000, 24, 132-138.
23. Balmain, A.; Gray, J.; Ponder, B. The genetics and genomics of cancer. Nat. Genet. 2003, 33, 238-244.
24. Knudson, A.G., Jr.; Strong, L. Mutation and cancer: A model for Wilms’ tumor of the kidney. J. Natl. Cancer Inst. 1972, 48, 313-324.
25. Sjöblom, T.; Jones, S.; Wood, L.D.; Parsons, D.W.; Lin, J.; Barber, T.D.; Mandelker, D.; Leary, R.J.; Ptak, J.; Silliman, N, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314, 268-274.
26. Gay, L.J.; Mitrou, P.N.; Keen, J.; Bowman, R.; Naguib, A.; Cooke, J.; Kuhnle, G.G.; Burns, P.A.; Luben, R.; Lentjes, M, et al. Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study. J. Pathol. 2012, 228, 405-415.
27. Schernhammer, E.S.; Giovannucci, E.; Kawasaki, T.; Rosner, B.; Fuchs, C.S.; Ogino, S. Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut 2010, 59, 794-799.
28. Barrow, T.M.; Michels, K.B. Epigenetic epidemiology of cancer. Biochem. Biophys. Res. Commun.2014, 455, 70-83.
29. Kohonen-Corish, M.R.J.; Tseung, J.; Chan, C.; Currey, N.; Dent, O.F.; Clarke, S.; Bokey, L.; Chapuis, P.H. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. Int. J. Cancer 2014, 134, 2820-2828.
30. Toyota, M.; Ahuja, N.; Ohe-Toyota, M.; Herman, J.G.; Baylin, S.B.; Issa, J.-P.J. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999, 96, 8681-8686.
31. Suzuki, H.; Yamamoto, E.; Maruyama, R.; Niinuma, T.; Kai, M. Biological significance of the CpG island methylator phenotype. Biochem. Biophys. Res. Commun. 2014, 455, 35-42.
32. Ogino, S.; Cantor, M.; Kawasaki, T.; Brahmandam, M.; Kirkner, G.J.; Weisenberger, D.J.; Campan, M.; Laird, P.W.; Loda, M.; Fuchs, C.S. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006, 55, 1000-1006.
33. Nosho, K.; Irahara, N.; Shima, K.; Kure, S.; Kirkner, G.J.; Schernhammer, E.S.; Hazra, A.; Hunter, D.J.; Quackenbush, J.; Spiegelman, D; et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008, 3, e3698.
34. Wood, L.D.; Parsons, D.W.; Jones, S.; Lin, J.; Sjöblom, T.; Leary, R.J.; Shen, D.; Boca, S.M.;Barber, T; Ptak, J, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318, 1108-1113.
35. Shen, L.; Toyota, M.; Kondo, Y.; Lin, E.; Zhang, L.; Guo, Y.; Hernandez, N.S.; Chen, X.; Ahmed, S.; Konishi, K, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 18654-18659.
36. Yagi, K.; Akagi, K.; Hayashi, H.; Nagae, G.; Tsuji, S.; Isagawa, T.; Midorikawa, Y.; Nishimura, Y.; Sakamoto, H.; Seto, Y, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin. Cancer Res. 2010, 16, 21-33.
37. Ogino, S.; Kawasaki, T.; Kirkner, G.J.; Loda, M.; Fuchs, C.S. CpG Island Methylator Phenotype-Low (CIMP-Low) in colorectal cancer: Possible associations with male sex and KRAS mutations. J. Mol. Diagn. 2006, 8, 582-588.
38. Hinoue, T.; Weisenberger, D.J.; Lange, C.P.E.; Shen, H.; Byun, H.-M.; Berg, D.V.D.; Malik, S.; Pan, F.; Noushmehr, H.; van Dijk, C.M, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012, 22, 271-282.
39. Rex, D.K.; Ahnen, D.J.; Baron, J.A.; Batts, K.P.; Burke, C.A.; Burt, R.W.; Goldblum, J.R.; Guillem, J.G.; Kahi, C.J.; Kalady, M.F, et al. Serrated lesions of the colorectum: Review and recommendations from an expert panel. Am. J. Gastroenterol. 2012, 107, 1315-1329.
40. Arain, M.A.; Sawhney, M.; Sheikh, S.; Anway, R.; Thyagarajan, B.; Bond, J.H.; Shaukat, A. CIMP status of interval colon cancers: Another piece to the puzzle. Am. J. Gastroenterol. 2010, 105, 1189-1195.
41. Nishihara, R.; Wu, K.; Lochhead, P.; Morikawa, T.; Liao, X.; Qian, Z.R.; Inamura, K.; Kim, S.A.; Kuchiba, A.; Yamauchi, M, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N. Engl. J. Med. 2013, 369, 1095-1105.
42. Chen, W.-S.; Leung, C.-M.; Pan, H.-W.; Hu, L.-Y.; Li, S.-C.; Ho, M.-R.; Tsai, K.-W. Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer. Oncol. Rep. 2012, 28, 1069-1076.
43. Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350-355.
44. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215-233.
45. Zhang, B.; Pan, X.; Cobb, G.P.; Anderson, T.A. microRNAs as oncogenes and tumor suppressors.Dev. Biol. 2007, 302, 1-12.
46. Zhang, Y.; Wang, X.; Xu, B.; Wang, B.; Wang, Z.; Liang, Y.; Zhou, J.; Hu, J.; Jiang, B. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol. Rep. 2013, 30, 1976-1984.
47. Fabbri, M.; Garzon, R.; Cimmino, A.; Liu, Z.; Zanesi, N.; Callegari, E.; Liu, S.; Alder, H.; Costinean, S.; Fernandez-Cymering, C, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 2007, 104, 15805-15810.
48. Ng, E.K.O.; Tsang, W.P.; Ng, S.S.M.; Jin, H.C.; Yu, J.; Li, J.J.; Röcken, C.; Ebert, M.P.A.; Kwok, T.T.; Sung, J.J.Y. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br. J. Cancer 2009, 101, 699-706.
49. Cui, H.; Onyango, P.; Brandenburg, S.; Wu, Y.; Hsieh, C.-L.; Feinberg, A.P. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002, 62, 6442-6446.
50. Sakatani, T.; Kaneda, A.; Iacobuzio-Donahue, C.A.; Carter, M.G.; de Witzel, S.B.; Okano, H.; Ko, M.S.H.; Ohlsson, R.; Longo, D.L.; Feinberg, A.P. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005, 307, 1976-1978.
51. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet.2002, 3, 415-428.
52. Tian, F.; Tang, Z.; Song, G.; Pan, Y.; He, B.; Bao, Q.; Wang, S. Loss of imprinting of IGF2correlates with hypomethylation of the H19 differentially methylated region in the tumor tissue of colorectal cancer patients. Mol. Med. Rep. 2012, 5, 1536-1540.
53. Hur, K.; Cejas, P.; Feliu, J.; Moreno-Rubio, J.; Burgos, E.; Boland, C.R.; Goel, A. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut 2013, 63, 635-646.
54. Frommer, M.; McDonald, L.E.; Millar, D.S.; Collis, C.M.; Watt, F.; Grigg, G.W.; Molloy, P.L.; Paul, C.L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 1992, 89, 1827-1831.
55. Laird, P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3, 253-266.
56. Pelizzola, M.; Ecker, J.R. The DNA methylome. FEBS Lett. 2011, 585, 1994-2000.
57. Wang, Q.; Gu, L.; Adey, A.; Radlwimmer, B.; Wang, W.; Hovestadt, V.; Bähr, M.; Wolf, S.; Shendure, J.; Eils, R, et al. Tagmentation-based whole-genome bisulfite sequencing. Nat. Protoc.2013, 8, 2022-2032.
58. Bardhan, K.; Liu, K. Epigenetics and colorectal cancer pathogenesis. Cancers 2013, 5, 676-713.
59. Kunde-Ramamoorthy, G.; Coarfa, C.; Laritsky, E.; Kessler, N.J.; Harris, R.A.; Xu, M.; Chen, R.; Shen, L.; Milosavljevic, A.; Waterland, R.A. Comparison and quantitative verification of mapping algorithms for whole-genome bisulfite sequencing. Nucleic Acids Res. 2014, 42, e43, doi:10.1093/nar/gkt1325.
60. Li, M.; Chen, W.; Papadopoulos, N.; Goodman, S.N.; Bjerregaard, N.C.; Laurberg, S.; Levin, B.; Juhl, H.; Arber, N.; Moinova, H, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 2009, 27, 858-863.
61. Naumov, V.A.; Generozov, E.V.; Zaharjevskaya, N.B.; Matushkina, D.S.; Larin, A.K.; Chernyshov, S.V.; Alekseev, M.V.; Shelygin, Y.A.; Govorun, V.M. Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips. Epigenetics 2013, 8, 921-934.
62. Wu, M.C.; Joubert, B.R.; Kuan, P.; Håberg, S.E.; Nystad, W.; Peddada, S.D.; London, S.J.A systematic assessment of normalization approaches for the Infinium 450 K methylation platform. Epigenetics 2014, 9, 318-329.
63. Zhuang, J.; Widschwendter, M.; Teschendorff, A.E. A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform. BMC Bioinform. 2012, 13, 59.
64. Dedeurwaerder, S.; Defrance, M.; Calonne, E.; Denis, H.; Sotiriou, C.; Fuks, F. Evaluation of the Infinium Methylation 450K technology. Epigenomics 2011, 3, 771-784.
65. Eads, C.A.; Danenberg, K.D.; Kawakami, K.; Saltz, L.B.; Blake, C.; Shibata, D.; Danenberg, P.V.; Laird, P.W. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28, e32.
66. Cottrell, S.E.; Distler, J.; Goodman, N.S.; Mooney, S.H.; Kluth, A.; Olek, A.; Schwope, I.; Tetzner, R.; Ziebarth, H.; Berlin, K. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res. 2004, 32, e10.
67. Kristensen, L.S.; Mikeska, T.; Krypuy, M.; Dobrovic, A. Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): High-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res. 2008, 36, e42.
68. He, Q.; Chen, H.-Y.; Bai, E.-Q.; Luo, Y.-X.; Fu, R.-J.; He, Y.-S.; Jiang, J.; Wang, H.-Q. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet. Cytogenet. 2010, 202, 1-10.
69. Yoo, C.B.; Jones, P.A. Epigenetic therapy of cancer: Past, present and future. Nat. Rev. Drug Discov.2006, 5, 37-50.
70. Winawer, S.; Fletcher, R.; Rex, D.; Bond, J.; Burt, R.; Ferrucci, J.; Ganiats, T.; Levin, T.; Woolf, S.; Johnson, D, et al. Colorectal cancer screening and surveillance: Clinical guidelines and rationale—Update based on new evidence. Gastroenterology 2003, 124, 544-560.
71. Hewitson, P.; Glasziou, P.P.; Irwig, L.; Towler, B.; Watson, E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. In Cochrane Database of Systematic Reviews; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 1996.
72. Mulero-Navarro, S.; Esteller, M. Epigenetic biomarkers for human cancer: The time is now. Crit. Rev. Oncol. Hematol. 2008, 68, 1-11.
73. Feinberg, A.P.; Ohlsson, R.; Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7, 21-33.
74. Huang, Z.-H.; Li, L.-H.; Yang, F.; Wang, J.-F. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J. Gastroenterol.2007, 13, 950-954.
75. Schwarzenbach, H.; Hoon, D.S.B.; Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11, 426-437.
76. Lofton-Day, C.; Model, F.; de Vos, T.; Tetzner, R.; Distler, J.; Schuster, M.; Song, X.; Lesche, R.; Liebenberg, V.; Ebert, M, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 2008, 54, 414-423.
77. Grützmann, R.; Molnar, B.; Pilarsky, C.; Habermann, J.K.; Schlag, P.M.; Saeger, H.D.; Miehlke, S.; Stolz, T.; Model, F.; Roblick, U.J, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008, 3, e3759.
78. Warren, J.D.; Xiong, W.; Bunker, A.M.; Vaughn, C.P.; Furtado, L.V.; Roberts, W.L.; Fang, J.C.; Samowitz, W.S.; Heichman, K.A. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011, 9, 133.
79. Grady, W.M.; Rajput, A.; Lutterbaugh, J.D.; Markowitz, S.D. Detection of aberrantly methylatedhMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 2001, 61, 900-902.
80. Zou, H.-Z.; Yu, B.-M.; Wang, Z.-W.; Sun, J.-Y.; Cang, H.; Gao, F.; Li, D.H.; Zhao, R.; Feng, G.-G.; Yi, J. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. 2002, 8, 188-191.
81. Lecomte, T.; Berger, A.; Zinzindohoué, F.; Micard, S.; Landi, B.; Blons, H.; Beaune, P.; Cugnenc, P.-H.; Laurent-Puig, P. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer 2002, 100, 542-548.
82. Leung, W.K.; To, K.-F.; Man, E.P.; Chan, M.W.; Bai, A.H.; Hui, A.J.; Chan, F.K.; Sung, J.J. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am. J. Gastroenterol. 2005, 100, 2274-2279.
83. Ebert, M.P.A.; Model, F.; Mooney, S.; Hale, K.; Lograsso, J.; Tonnes-Priddy, L.; Hoffmann, J.; Csepregi, A.; Röcken, C.; Molnar, B, et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology 2006, 131, 1418-1430.
84. Herbst, A.; Rahmig, K.; Stieber, P.; Philipp, A.; Jung, A.; Ofner, A.; Crispin, A.; Neumann, J.;Lamerz, R.; Kolligs, F.T. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am. J. Gastroenterol. 2011, 106, 1110-1118.
85. Tang, D.; Liu, J.; Wang, D.; Yu, H.; Li, Y.; Zhang, J. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin. Investig. Med. 2011, 34, E88-E95.
86. Tan, S.-H.; Ida, H.; Lau, Q.-C.; Goh, B.-C.; Chieng, W.-S.; Loh, M.; Ito, Y. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol. Rep. 2007, 18, 1225-1230.
87. Weirich, C.S.; Erzberger, J.P.; Barral, Y. The septin family of GTPases: Architecture and dynamics. Nat. Rev. Mol. Cell Biol. 2008, 9, 478-489.
88. Liang, G.; Salem, C.E.; Yu, M.C.; Nguyen, H.D.; Gonzales, F.A.; Nguyen, T.T.; Nichols, P.W.; Jones, P.A. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics 1998, 53, 260-268.
89. Osborn, N.K.; Ahlquist, D.A. Stool screening for colorectal cancer: Molecular approaches. Gastroenterology 2005, 128, 192-206.
90. Itzkowitz, S.H.; Jandorf, L.; Brand, R.; Rabeneck, L.; Schroy, P.C., III; Sontag, S.; Johnson, D.; Skoletsky, J.; Durkee, K.; Markowitz, S, et al. Improved fecal DNA test for colorectal cancer screening. Clin. Gastroenterol. Hepatol. 2007, 5, 111-117.
91. Zou, H.; Harrington, J.J.; Shire, A.M.; Rego, R.L.; Wang, L.; Campbell, M.E.; Oberg, A.L.; Ahlquist, D.A. Highly methylated genes in colorectal neoplasia: Implications for screening. Cancer Epidemiol. Biomark. Prev. 2007, 16, 2686-2696.
92. Chen, W.-D.; Han, Z.J.; Skoletsky, J.; Olson, J.; Sah, J.; Myeroff, L.; Platzer, P.; Lu, S.;Dawson, D.; Willis, J, et al. Detection in fecal DNA of colon cancer—Specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst. 2005, 97, 1124-1132.
93. Wang, D.-R. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J. Gastroenterol. 2008, 14, 524.
94. Müller, H.M.; Oberwalder, M.; Fiegl, H.; Morandell, M.; Goebel, G.; Zitt, M.; Mühlthaler, M.; Öfner, D.; Margreiter, R.; Widschwendter, M. Methylation changes in faecal DNA: A marker for colorectal cancer screening? Lancet 2004, 363, 1283-1285.
95. Glöckner, S.C.; Dhir, M.; Yi, J.M.; McGarvey, K.E.; Neste, L.V.; Louwagie, J.; Chan, T.A.; Kleeberger, W.; de Bruïne, A.P.; Smits, K.M, et al. Methylation of TFPI2 in stool DNA: A potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009, 69, 4691-4699.
96. Hellebrekers, D.M.E.I.; Lentjes, M.H.F.M.; van den osch, S.M.; Melotte, V.; Wouters, K.A.D.; Daenen, K.L.J.; Smits, K.M.; Akiyama, Y.; Yuasa, Y.; Sanduleanu, S, et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin. Cancer Res. 2009, 15, 3990-3997.
97. Melotte, V.; Lentjes, M.H.F.M.; van den Bosch, S.M.; Hellebrekers, D.M.E.I.; de Hoon, J.P.J.; Wouters, K.A.D.; Daenen, K.L.J.; Partouns-Hendriks, I.E.J.M.; Stessels, F.; Louwagie, J, et al. N-Myc Downstream-Regulated Gene 4 (NDRG4): A candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl. Cancer Inst. 2009, 101, 916-927.
98. Petko, Z.; Ghiassi, M.; Shuber, A.; Gorham, J.; Smalley, W.; Washington, M.K.; Schultenover, S.; Gautam, S.; Markowitz, S.D.; Grady, W.M. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin. Cancer Res. 2005, 11, 1203-1209.
99. Chang, E.; Park, D.I.; Kim, Y.J.; Kim, B.K.; Park, J.H.; Kim, H.J.; Cho, Y.K.; Sohn, C.I.; Jeon, W.K.; Kim, B.I, et al. Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: A preliminary report in Korean patients. Hepatogastroenterology 2010, 57, 720-727.
100. Itzkowitz, S.; Brand, R.; Jandorf, L.; Durkee, K.; Millholland, J.; Rabeneck, L.; Schroy, P.C.; Sontag, S.; Johnson, D.; Markowitz, S, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am. J. Gastroenterol. 2008, 103, 2862-2870.
101. Shao, S.; Liao, X.; Zhang, Y.; Qiu, J.; Zhang, X.; Yang, G. Multi-gene methylation detection increases positive methylation rate in colorectal cancer. Chin. J. Gastrointest. Surg. 2012, 15, 629-632.
102. Song, B.P.; Jain, S.; Lin, S.Y.; Chen, Q.; Block, T.M.; Song, W.; Brenner, D.E.; Su, Y.-H. Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J. Mol. Diagn. 2012, 14, 112-119.
103. Ahlquist, D.A; Taylor, W.R; Mahoney, D.W; Zou, H; Domanico, M; Thibodeau, S.N; Boardman, L.A.; Berger, B.M. Lidgard, G.P. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin. Gastroenterol. Hepatol. 2012, 10, 272-277.e1.
104. Dong, S.M.; Traverso, G.; Johnson, C.; Geng, L.; Favis, R.; Boynton, K.; Hibi, K.; Goodman, S.N.; D’Allessio, M.; Paty, P, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J. Natl. Cancer Inst. 2001, 93, 858-865.
105. Zoratto, F.; Rossi, L.; Verrico, M.; Papa, A.; Basso, E.; Zullo, A.; Tomao, L.; Romiti, A.; Russo, G.L.; Tomao, S. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: Implications for molecular diagnosis. Tumor Biol. 2014, 35, 6195-6206
106. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759-767
107. Ahlquist, D.A.; Skoletsky, J.E.; Boynton, K.A.; Harrington, J.J.; Mahoney, D.W.; Pierceall, W.E.; Thibodeau, S.N.; Shuber, A.P. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel. Gastroenterology 2000, 119, 1219-1227.
108. Brand, R.E.; Ross, M.E.; Shuber, A.P. Reproducibility of a multitarget stool-based DNA assay for colorectal cancer detection. Am. J. Gastroenterol. 2004, 99, 1338-1341.
109. Calistri, D.; Rengucci, C.; Bocchini, R.; Saragoni, L.; Zoli, W.; Amadori, D. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin. Gastroenterol. Hepatol. 2003, 1, 377-383.
110. Syngal, S.; Stoffel, E.; Chung, D.; Willett, C.; Schoetz, D.; Schroy, P.; Jagadeesh, D.; Morel, K.; Ross, M. Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer 2006, 106, 277-283.
111. Tagore, K.S.; Lawson, M.J.; Yucaitis, J.A.; Gage, R.; Orr, T.; Shuber, A.P.; Ross, M.E. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin. Colorectal Cancer 2003, 3, 47-53.
112. Miller, S.; Steele, S. Novel molecular screening approaches in colorectal cancer. J. Surg. Oncol.2012, 105, 459-467.
113. Cologuard Cost: How Much Is Cologuard? (accessed on 12 December 2014).
114. Levin, B.; Lieberman, D.A.; McFarland, B.; Smith, R.A.; Brooks, D.; Andrews, K.S.; Dash, C.; Giardiello, F.M.; Glick, S.; Levin, T.R, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on colorectal cancer, and the American College of Radiology. CA Cancer J. Clin. 2008, 58, 130-160.
115. Yu, J.; Ma, X.; Cheung, K.F.; Li, X.; Tian, L.; Wang, S.; Wu, C.W.; Wu, W.K.K.; He, M.; Wang, M, et al. Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer. Oncogene 2010, 29, 6464-6474.
116. Tsai, H.-C.; Baylin, S.B. Cancer epigenetics: Linking basic biology to clinical medicine. Cell Res. 2011, 21, 502-517.
117. Wallner, M.; Herbst, A.; Behrens, A.; Crispin, A.; Stieber, P.; Göke, B.; Lamerz, R.; Kolligs, F.T. Methylation of Serum DNA is an independent prognostic marker in colorectal cancer. Clin. Cancer Res. 2006, 12, 7347-7352.
118. Philipp, A.B.; Stieber, P.; Nagel, D.; Neumann, J.; Spelsberg, F.; Jung, A.; Lamerz, R.; Herbst, A.; Kolligs, F.T. Prognostic role of methylated free circulating DNA in colorectal cancer. Int. J. Cancer 2012, 131, 2308-2319.
119. Herbst, A.; Wallner, M.; Rahmig, K.; Stieber, P.; Crispin, A.; Lamerz, R.; Kolligs, F.T. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. J. Gastroenterol. 2009, 21, 565-569.
120. Kim, J.C.; Choi, J.S.; Roh, S.A.; Cho, D.H.; Kim, T.W.; Kim, Y.S. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann. Surg. Oncol. 2010, 17, 1767-1776.
121. Shima, K.; Nosho, K.; Baba, Y.; Cantor, M.; Meyerhardt, J.A.; Giovannucci, E.L.; Fuchs, C.S.; Ogino, S. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int. J. Cancer 2011, 128, 1080-1094.
122. Veganzones-de-Castro, S.; Rafael-Fernández, S.; Vidaurreta-Lázaro, M.; de-la Orden, V.; Mediero-Valeros, B.; Fernández, C.; Maestro-delasCasas, M.L. p16 gene methylation in colorectal cancer patients with long-term follow-up. Rev. Esp. Enfermedades Dig. 2012, 104, 111-117.
123. Wang, S.; Dong, Y.; Zhang, Y.; Wang, X.; Xu, L.; Yang, S.; Li, X.; Dong, H.; Xu, L.; Su, L, et al.DACT2 is a functional tumor suppressor through inhibiting Wnt/β-catenin pathway and associated with poor survival in colon cancer. Oncogene 2014, doi:10.1038/onc.2014.201.
124. Smits, K.M.; Cleven, A.H.; Weijenberg, M.P.; Hughes, L.A.; Herman, J.G.; de Bruïne, A.P.; van Engeland, M. Pharmacoepigenomics in colorectal cancer: A step forward in predicting prognosis and treatment response. Pharmacogenomics 2008, 9, 1903-1916.
125. Grady, W.M.; Pritchard, C.C. Molecular alterations and biomarkers in colorectal cancer. Toxicol. Pathol. 2014, 42, 124-139.
126. Soengas, M.S.; Lowe, S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22, 3138-3151.
127. Widschwendter, M.; Siegmund, K.D.; Müller, H.M.; Fiegl, H.; Marth, C.; Müller-Holzner, E.; Jones, P.A.; Laird, P.W. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004, 64, 3807-3813.
128. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343, 1350-1354.
129. Ebert, M.P.A.; Tänzer, M.; Balluff, B.; Burgermeister, E.; Kretzschmar, A.K.; Hughes, D.J.; Tetzner, R.; Lofton-Day, C.; Rosenberg, R.; Reinacher-Schick, A.C, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N. Engl. J. Med. 2012, 366, 44-53.
130. Gomez, A.; Ingelman-Sundberg, M. Pharmacoepigenetics: Its role in interindividual differences in drug response. Clin. Pharmacol. Ther. 2009, 85, 426-430.
131. Weisenberger, D.J.; Siegmund, K.D.; Campan, M.; Young, J.; Long, T.I.; Faasse, M.A.; Kang, G.H.; Widschwendter, M.; Weener, D.; Buchanan, D, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006, 38, 787-793.
132. Barault, L.; Charon-Barra, C.; Jooste, V.; de la Vega, M.F.; Martin, L.; Roignot, P.; Rat, P.; Bouvier, A.-M.; Laurent-Puig, P.; Faivre, J, et al. Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases. Cancer Res. 2008, 68, 8541-8546.
133. Ahn, J.B.; Chung, W.B.; Maeda, O.; Shin, S.J.; Kim, H.S.; Chung, H.C.; Kim, N.K.; Issa, J.-P.J. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 2011, 117, 1847-1854.
134. Rhee, Y.-Y.; Kim, M.J.; Bae, J.M.; Koh, J.M.; Cho, N.-Y.; Juhnn, Y.-S.; Kim, D.; Kang, G.H. Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level. Ann. Surg. Oncol. 2012, 19, 3441-3448.
135. Jo, P.; Jung, K.; Grade, M.; Conradi, L.-C.; Wolff, H.A.; Kitz, J.; Becker, H.; Rüschoff, J.; Hartmann, A.; Beissbarth, T, et al. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery 2012, 151, 564-570.
136. Li, X.; Hu, F.; Wang, Y.; Yao, X.; Zhang, Z.; Wang, F.; Sun, G.; Cui, B.-B.; Dong, X.; Zhao, Y. CpG island methylator phenotype and prognosis of colorectal cancer in northeast China. BioMed Res. Int. 2014, 2014, e236361.
137. Samowitz, W.S.; Curtin, K.; Wolff, R.K.; Tripp, S.R.; Caan, B.J.; Slattery, M.L. Microsatellite instability and survival in rectal cancer. Cancer Causes Control 2009, 20, 1763-1768.
138. Kim, J.H.; Shin, S.H.; Kwon, H.J.; Cho, N.Y.; Kang, G.H. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 2009, 455, 485-494.
139. Min, B.-H.; Bae, J.M.; Lee, E.J.; Yu, H.S.; Kim, Y.-H.; Chang, D.K.; Kim, H.C.; Park, C.K.; Lee, S.-H.; Kim, K.-M, et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011, 11, 344.
140. Ward, R.L.; Cheong, K.; Ku, S.-L.; Meagher, A.; O’Connor, T.; Hawkins, N.J. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J. Clin. Oncol. 2003, 21, 3729-3736.
141. Iacopetta, B.; Kawakami, K.; Watanabe, T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: Is the CpG island methylator phenotype the 5-fluorouracil responsive subgroup? Int. J. Clin. Oncol. 2008, 13, 498-503.
142. Shiovitz, S.; Bertagnolli, M.M.; Renfro, L.A.; Nam, E.; Foster, N.R.; Dzieciatkowski, S.; Luo, Y.; Lao, V.V.; Monnat, R.J.; Emond, M.J, et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 2014, 147, 637-645.
143. Ogino, S.; Kawasaki, T.; Nosho, K.; Ohnishi, M.; Suemoto, Y.; Kirkner, G.J.; Fuchs, C.S. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int. J. Cancer 2008, 122, 2767-2773.
144. Estécio, M.R.H.; Gharibyan, V.; Shen, L.; Ibrahim, A.E.K.; Doshi, K.; He, R.; Jelinek, J.; Yang, A.S.; Yan, P.S.; Huang, T.H.-M, et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2007, 2, e399.
145. Ogino, S.; Nishihara, R.; Lochhead, P.; Imamura, Y.; Kuchiba, A.; Morikawa, T.; Yamauchi, M.; Liao, X.; Qian, Z.R.; Sun, R, et al. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J. Natl. Cancer Inst. 2013, 105, 130-140.
146. Ogino, S.; Nosho, K.; Kirkner, G.J.; Kawasaki, T.; Chan, A.T.; Schernhammer, E.S.; Giovannucci, E.L.; Fuchs, C.S. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl. Cancer Inst. 2008, 100, 1734-1738.
147. Ogino, S.; Lochhead, P.; Chan, A.T.; Nishihara, R.; Cho, E.; Wolpin, B.M.; Meyerhardt, J.A.; Meissner, A.; Schernhammer, E.S.; Fuchs, C.S, et al. Molecular pathological epidemiology of epigenetics: Emerging integrative science to analyze environment, host, and disease. Mod. Pathol. 2013, 26, 465-484.
148. Ogino, S.; Chan, A.T.; Fuchs, C.S.; Giovannucci, E. Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut 2011, 60, 397-411.
149. Imperiale, T.F.; Ransohoff, D.F.; Itzkowitz, S.H. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 2014, 371, 187-188.